Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone732-537-6200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.52 billion
Profitability
Miscellaneous
Employees12,300
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Catalent (NYSE:CTLT) Frequently Asked Questions
What is Catalent's stock symbol?
Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."
How were Catalent's earnings last quarter?
Catalent Inc (NYSE:CTLT) released its quarterly earnings results on Tuesday, August, 27th. The company reported $0.65 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.62 by $0.03. The firm earned $725.70 million during the quarter, compared to analysts' expectations of $719.20 million. Catalent had a return on equity of 15.89% and a net margin of 5.46%. The business's revenue was up 5.9% on a year-over-year basis. During the same period last year, the firm posted $0.67 EPS. View Catalent's Earnings History.
When is Catalent's next earnings date?
What guidance has Catalent issued on next quarter's earnings?
Catalent updated its FY20 earnings guidance on Tuesday, August, 27th. The company provided earnings per share (EPS) guidance of ~$1.89-2.06 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.98. The company issued revenue guidance of $2.78-2.88 billion, compared to the consensus revenue estimate of $2.84 billion.
What price target have analysts set for CTLT?
6 analysts have issued 1 year price objectives for Catalent's shares. Their predictions range from $45.00 to $64.00. On average, they expect Catalent's share price to reach $56.8333 in the next twelve months. This suggests a possible upside of 12.2% from the stock's current price. View Analyst Price Targets for Catalent.
What is the consensus analysts' recommendation for Catalent?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalent.
Has Catalent been receiving favorable news coverage?
Media stories about CTLT stock have trended negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Catalent earned a daily sentiment score of -2.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Catalent.
Who are some of Catalent's key competitors?
Some companies that are related to Catalent include Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TAK), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Mylan (MYL), Array Biopharma (ARRY), Elanco Animal Health (ELAN), Alnylam Pharmaceuticals (ALNY), Ono Pharmaceutical (OPHLF) and Ionis Pharmaceuticals (IONS).
What other stocks do shareholders of Catalent own?
Who are Catalent's key executives?
Catalent's management team includes the folowing people:
- Mr. John R. Chiminski, Chairman & CEO (Age 55)
- Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 47)
- Mr. Steven L. Fasman, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
- Mr. Jonathan Arnold, Pres of Oral Drug Delivery Bus. Unit (Age 53)
- Mr. Alessandro Maselli, Pres & COO (Age 47)
Who are Catalent's major shareholders?
Catalent's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (15.72%), Janus Henderson Group PLC (11.87%), BlackRock Inc. (9.82%), BlackRock Inc. (9.82%), Vanguard Group Inc. (9.23%) and Earnest Partners LLC (1.74%). Company insiders that own Catalent stock include Aristippos Gennadios, Barry Littlejohns, Donald E Morel, Jr, Gregory T Lucier, John J Greisch, John R Chiminski, Lance Miyamoto, Peter L Buzy, Steven L Fasman, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent.
Which major investors are selling Catalent stock?
CTLT stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Schroder Investment Management Group, Brown Advisory Inc., Emerald Advisers LLC, D. E. Shaw & Co. Inc., Janus Henderson Group PLC, Price T Rowe Associates Inc. MD and Jennison Associates LLC. Company insiders that have sold Catalent company stock in the last year include Aristippos Gennadios, Barry Littlejohns, John R Chiminski, Lance Miyamoto, Steven L Fasman and William Downie. View Insider Buying and Selling for Catalent.
Which major investors are buying Catalent stock?
CTLT stock was bought by a variety of institutional investors in the last quarter, including Highline Capital Management L.P., Wells Fargo & Company MN, Viking Global Investors LP, Nuveen Asset Management LLC, BlackRock Inc., BlackRock Inc., First Trust Advisors LP and Ironvine Capital Partners LLC. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, Gregory T Lucier, John J Greisch, Peter L Buzy and Uwe Roehrhoff. View Insider Buying and Selling for Catalent.
How do I buy shares of Catalent?
Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Catalent's stock price today?
One share of CTLT stock can currently be purchased for approximately $50.64.
How big of a company is Catalent?
Catalent has a market capitalization of $7.39 billion and generates $2.52 billion in revenue each year. The company earns $137.40 million in net income (profit) each year or $1.62 on an earnings per share basis. Catalent employs 12,300 workers across the globe.View Additional Information About Catalent.
What is Catalent's official website?
How can I contact Catalent?
Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]
MarketBeat Community Rating for Catalent (NYSE CTLT)
MarketBeat's community ratings are surveys of what our community members think about Catalent and other stocks. Vote "Outperform" if you believe CTLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
